Trial Search Results
Vitamin D and Type 2 Diabetes Study
The goal of the Vitamin D and type 2 diabetes (D2d) study is to determine if vitamin D supplementation works to delay the onset of type 2 diabetes in people at risk for the disease and to gain a better understand how vitamin D affects glucose (sugar) metabolism.
Stanford is currently accepting patients for this trial.
Tufts Medical Center
Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Dietary Supplement: Vitamin D (Cholecalciferol)
- Other: Placebo
1. Pre-diabetes ("at increased risk for diabetes") defined by meeting 2-out-of-3 of the
following glycemic criteria at the baseline visit:
1. Fasting plasma glucose (FPG) 100-125 mg/dL
2. 2-hour plasma glucose (2hPG) 140-199 mg/dL
3. Hemoglobin A1c (HbA1c) 5.7-6.4%
2. Age ≥ 30 years .(≥25 years for people of the following races: American-Indian, Alaska
Native, Native Hawaiian or Other Pacific Islander).
3. Body Mass Index ≥ 24.0 (22.5 for Asians) and ≤ 42.0 kg/m2
4. Provision of signed and dated written informed consent prior to any study procedures.
Major Exclusion Criteria:
1. Diabetes based on either of the following criteria:
1. History (past 1 year) of hypoglycemic pharmacotherapy (oral or injectable
medication approved by the FDA for type 2 diabetes), used for any condition (e.g.
pre-diabetes, diabetes, polycystic ovarian syndrome.
2. Meeting the diagnosis criteria for diabetes
2. History (past 3 years) of hyperparathyroidism, nephrolithiasis or hypercalcemia.
3. Pregnancy (past 1 year by report or positive pregnancy test at screening), intent to
become pregnant in the next 4 years or unprotected intercourse. History of gestational
diabetes is not an exclusion criterion.
4. Currently breastfeeding.
Ages Eligible for Study
30 Years - N/A
Genders Eligible for Study